Advertisement

Topics

Companies Related to "Exercise and Phytoestrogens: Effect on Factors Predisposing to Cardiovascular Disease(CVD) in Postmenopausal Women" [Most Relevant Company Matches] [Advanced Search Results] RSS

08:28 EST 15th December 2018 | BioPortfolio

Here are the most relevant search results for "Exercise and Phytoestrogens: Effect on Factors Predisposing to Cardiovascular Disease(CVD) in Postmenopausal Women" found in our extensive corporate database of over 50,000 company records.

Showing "Exercise Phytoestrogens Effect Factors Predisposing Cardiovascular Disease Postmenopausal" Companies 1–25 of 3,300+

Relevant

Brilliant Biometrics

Brilliant Biometrics is dedicated to developing wearable technology that enhances the well-being of individuals and communities. We are a diverse and creative team of engineers, industrial designers, artists, psychologists and exercise enthusiasts. After experimenting with many exercise heart rate monitors, we realized that it is actually very difficult to...


miRagen Therapeutics, Inc.

Cardiovascular disease is the leading cause of death globally. Astonishingly, in the United States, every 37 seconds a person dies from cardiovascular disease. For survivors, life changes dramatically after an adverse heart event. Because of the significant toll that cardiovascular and muscle disease takes on patients, miRagen Therapeutics, Inc., was found...

MyoKardia, Inc.

MyoKardia is dedicated to revolutionizing the treatment of genetic cardiovascular disease. The company’s proprietary platform combines recent breakthroughs in muscle biology with leading-edge cardiovascular disease genetics. This personalized, genetically targeted approach focuses on the underlying cause of disease and has the potential to drastically...


Rodaris Pharmaceuticals Limited

The Company has had unparalleled success in unravelling the biochemistry and chemistry of small molecules that mediate the individual signalling events of hormones and growth factors. It has produced novel libraries of synthetic mediators which offer exciting new therapeutic targets for treatment of a wide range of endocrine, immunological, cardiovascular and neurological disease.

Curis

This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Curis' future financial position, business strategy and plans and objectives of management for future operations. We may use such words as "believes," "expects," "anticipates," "plans," "estimates," and similar expressions to identify these for...

CorMedix Inc.

CorMedix Inc. is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix’s goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications, in effect, tr...

Sangamo BioSciences

Sangamo BioSciences develops and markets novel transcription factors capable of regulating genes. The company’s powerful Universal Gene Recognition™ technology enables the engineering of a particular class of transcription factors known as zinc finger DNA-binding proteins, or ZFPs. By engineering ZFPs so that they can recognize a specific gene, Sangamo has created ZFP transcription factors tha...

Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical tri...

CardioVascular BioTherapeutics

CardioVascular BioTherapeutics, Inc. (OTC/BB: CVBT) is a biopharmaceutical company focused on developing protein drug candidates to be used in the treatment of cardiovascular disease, the worldwide leading cause of death. The Company is developing injectable and topical formulations of its active pharmacological ingredient (API) to facilitate the growth of new blood vessels (angiogenesis) in the h...

The Lipoprotein(a) Foundation

Because approximately 63 million Americans have high Lipoprotein(a) and are at risk of premature cardiovascular disease, the vision for the foundation is: To live in a world where high Lipoprotein(a) is routinely diagnosed, treated and family screened. The mission is to prevent cardiovascular events due to high Lipoprotein(a) by diagnosing this inherited r...

Aterovax SA

Aterovax is developing innovative products for the cardiovascular disease market based on a unique understanding of atherosclerosis, the condition responsible for most cardiovascular problems. Aterovax’s first product is a diagnostic blood test to measure activity of secretory phospholipase A2 (sPLA2), a powerful biomarker that provides physicians wit...

Osteometer MediTech, Inc

Osteometer A/S was founded in 1989 by Dr. Claus Christiansen and Dr. Bente Juel Riis on the basis of 25 years of research within osteoporosis. For more than two decades Dr. Claus Christiansen has been involved in internationally recognized research on the problems of the postmenopausal woman. He has specialized in the disease of brittle bones (osteoporosis) and bone diseases in general. The main g...

Myogen, Inc.

Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. We believe that our advanced understanding of the biology of cardiovascular disease combined with our clinical development expertise in cardiovascular therapeutics provide us with the capability to discover novel therapies, ...

Cardiovascular Consultants, Ltd.

Cardiovascular Consultants, Ltd., founded in 1986 by Dr. Andrei Damian, is dedicated to providing patients in Phoenix and surrounding areas with the most advanced and appropriate cardiovascular care to achieve quality of life. Today Cardiovascular Consultants has 38 physicians and 15 mid-level providers in 17 locations, and is one of the largest cardiovasc...

Aviir, Inc.

Founded in 2005 by cardiologists and researchers from the Stanford University School of Medicine , Aviir is focused on the discovery, development and commercialization of innovative diagnostic and predictive cardiovascular tests, employing state of the art laboratory diagnostic methods. Aviir’s CLIA laboratory in Irvine, CA offers a range of tests for...

Cardiovascular Consultants Ltd.

Cardiovascular Consultants Ltd., founded in 1986 by Dr. Andrei Damian, is dedicated to providing patients in Phoenix and surrounding areas with the most advanced and appropriate cardiovascular care to achieve quality of life. Today Cardiovascular Consultants has 36 physicians and 14 mid-level providers in 15 locations, and is one of the largest cardiovascu...

Eminent effect

The eminent effect is a consultancy aiming to stand out from the crowd in tackling many of today’s people and business challenges. The company offers organisation specific training, development, sales/marketing and interim management solutions not off the shelf packages.Primarily working within the NHS, Pharmaceutical and Biotechnology sectors, the eminent effect personnel can offer experience g...

Cardiovascular Institute of the South (CIS)

CIS is one of the most respected groups of cardiologists, representing nearly every specialty in heart and circulatory medicine. With a team of nearly 450 dedicated team members, CIS serves communities throughout Louisiana, as well as national and international patients, at its 10 clinics. CIS consistently positions itself at the forefront of technology by providing the most up-to-date technolog...

Cardiovascular Research Foundation of Southern California

The CVRF is a 501(3)(c) non-profit charitable organization that was founded in 2007 as the non-profit research arm of the Cardiovascular Medical Group of Southern California, a specialty cardiovascular practice that has been in practice for nearly 40 years. The Foundation currently is engaged in numerous research studies and aims to raise awareness of the ...

The Richard B. and Lynne V. Cheney Cardiovascular Institute

The Richard B. and Lynne V. Cheney Cardiovascular Institute at The George Washington University was established in 2006. The Institute's mission is to promote clinical research, education, patient care and community service with the goal of accelerating the pace of scientific discovery, reducing mortality and improving the quality of life of Americans with cardiovascular disease. For more informa...

VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in plaque, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of dr...

Embrella Cardiovascular, Inc.

Embrella Cardiovascular™, Inc., is dedicated to creating a new standard-of-care for cerebral embolic protection during cardiovascular procedures. Embrella's Embolic Deflector®, an aortic embolic protection device which acts as a protective shield to reduce the incidence of embolization to the brain, has been granted CE Mark approval. Embrella is a ...

Pivotal Therapeutics Inc.

With offices in Toronto, Canada and Boca Raton, Florida, Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF; CNSX: PVO) specialty pharmaceutical company with a focus on cardiovascular and overall health. Pivotal Therapeutics' lead product VASCAZENTM is a prescription only medical food formulated to meet the dietary Omega-3 deficient needs of patients ...

Esperion

We discover and develop pharmaceutical products for the treatment of cardiovascular disease, which is disease of the heart and the body's blood vessels and related organs. We intend to commercialize a novel class of drugs that focus on a new treatment approach we call "HDL Therapy," which is based on our understanding of high density lipoprotein, or HDL, function. HDL is the primary facilitator of...

Amarin Corporation plc

Amarin is a clinical-stage biopharmaceutical company with a focus on cardiovascular disease. The Company’s lead product candidate is AMR101(ethyl icosapentate), which is entering Phase 3 clinical trials for the treatment of very high triglycerides and high triglycerides in patients with mixed dyslipidemia, under Special Protocol Assessment agreements ...


More From BioPortfolio on "Exercise and Phytoestrogens: Effect on Factors Predisposing to Cardiovascular Disease(CVD) in Postmenopausal Women"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks